Human Leukocyte Antigen-DR Expression on Monocytes Is a Useful Predictor in a Systemic Inflammation Response-Based...

Area of Science:

• Oncology
• Immunology

Background:

• Inflammation and immune evasion are key drivers of cancer development and progression.
• Elevated Systemic Inflammation Response Index (SIRI) and reduced monocyte Human Leukocyte Antigen-DR (HLA-DR) expression are linked to poorer prognoses in non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To investigate the relationship between SIRI and monocyte HLA-DR expression in advanced NSCLC.
• To develop a predictive model integrating SIRI and HLA-DR for improved survival prediction in NSCLC.

Main Methods:

• SIRI was calculated, and monocyte HLA-DR expression was measured via flow cytometry in 58 advanced NSCLC patients (Stage IIIB-IV).
• Statistical analyses included log-rank tests and multivariate Cox proportional hazard regression models.

Main Results:

• High SIRI and low monocyte HLA-DR expression were independently associated with poor progression-free survival (PFS) and overall survival (OS).
• A significant inverse correlation was observed between SIRI and monocyte HLA-DR expression.
• A nomogram was developed for predicting PFS and OS, integrating both biomarkers.

Conclusions:

• Systemic inflammation in advanced NSCLC, indicated by SIRI, correlates with decreased monocyte HLA-DR expression, potentially impairing antigen presentation.
• The combined prognostic model using SIRI and HLA-DR enhances short-term survival prediction for advanced NSCLC patients.